Company intelligence / Profile preview

Taizhou Hongyun Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Taizhou Hongyun Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company established in 2018 and based in Jiangsu Province. The company focuses on the research and development of small molecule drugs targeting oncology indications, particularly non-small cell lung cancer and solid tumors. Its pipeline includes at least three known assets with one lead candidate currently in Phase 1/2 clinical trials targeting multiple mutations of the epidermal growth factor receptor relevant to resistant forms of non-small cell lung cancer. Other assets are at preclinical stages.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

RC-08

Preclinical

Beyond the preview

Go deeper on Taizhou Hongyun Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taizhou Hongyun Pharmaceutical.

Explore the full profile